Percheron Therapeutics Ord Shs PER

Primary Symbol: ATHJF

Healthcare

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

OTCPK:ATHJF - Post by User

Percheron Therapeutics Ord Shs

<< Previous

Bullboard Posts

Post by mart33on Mar 27, 2008 7:26pm

341 Views

Post# 14914017

opportunities in the Chinese

On March 18.2008 Perot Systems Corporation NYSE: PER and ChinaSoft International (HK8216) today announced that they have agreed to cooperatively develop mutually beneficial opportunities in the Chinese Healthcare market. After this news stock run up from 13.50 to 15.50 and then reversed. Hopefully 14.50 will work as a support.

<< Previous

Bullboard Posts

One of the strongest contenders to lead Canada’s cannabis market